- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Benralizumab – March 2018
Benralizumab: 30 mg in 1 mL injection; Fasenra®
Last updated
29 June 2018